Ferric maltol - Shield Therapeutics

Drug Profile

Ferric maltol - Shield Therapeutics

Alternative Names: Feraccru; Iron (III) maltol; ST-10; ST10-021

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Cambridge; University of London
  • Developer Shield Therapeutics
  • Class Antianaemics; Ferric compounds; Pyrones; Small molecules
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia

Most Recent Events

  • 27 Feb 2018 CHMP recommends approval of Ferric maltol for Iron deficiency (In adults with iron deficiency (ID) with or without anaemia) in European Union
  • 05 Feb 2018 The phase III AEGIS-CKD trial, for the treatment of iron deficiency anaemia in chronic kidney disease patients, fails to meet its primary endpoint of haemoglobin response, according to topline results
  • 10 Oct 2017 Shield Therapeutics completes enrolment in the phase III AEGIS-CKD trial in Iron deficiency anaemia in USA (NCT02968368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top